Cellceutix Corp (OTCQB:CTIX)

Cellceutix Corporation, a development stage biopharmaceutical company, engages in the discovery and development of small molecule drugs to treat diseases primarily in the areas of cancer and inflammatory disease. Its product candidates include Kevetrin, which is in Phase 1 trial for various solid tumor cancer types in patients with advanced-stage cancers; and various preclinical stage products comprising KM-133 for the treatment of psoriasis; KM 391 for the treatment of autism; KM 277 for the treatment of arthritis; and KM 278 for the treatment of asthma and osteoarthritis. The company’s products under early research and development consist of KM 362 for the treatment of MS/ALS/Parkinsons diseases; KM-3174 for the treatment of cancer; and KM-732 for the treatment of hypertensive emergency. Cellceutix Corporation was founded in 2007 and is headquartered in Beverly, Massachusetts.

Web site: http://www.cellceutix.com

Last updated December 24, 2012